Professional Documents
Culture Documents
Impact of preformulation on
drug development
Sonali S Bharate & Ram A Vishwakarma†
1. Introduction Indian Institute of Integrative Medicine (CSIR), Jammu, India
5. Chirality
essential for selecting right NCEs in order to reduce attrition rate in the late
6. Bulk properties (particle size
and size distribution, flow,
stage development.
dissolution, etc.) Areas covered: This article describes the significance of preformulation
research in drug discovery and development. Various crucial preformulation
7. Hygroscopicity
parameters with case studies have been discussed.
8. Drug stability Expert opinion: Physicochemical and biopharmaceutical characterization of
9. Drug solubility NCEs is a decisive parameter during product development. Early prediction
10. Physical incompatibilities of these properties helps in selecting suitable physical form (salt, polymorph,
11. Biopharmaceutical etc.) of the candidate. Based on pharmacokinetic and efficacy/toxicity studies,
aspects -- absorption, suitable formulation for Phase I clinical studies can be developed. Overall
distribution, metabolism and these activities contribute in streamlining efficacy/toxicology evaluation,
For personal use only.
1. Introduction
to have quick proof of concept for first-time-in-man studies to particularly in wet granulation. It often becomes difficult to
make a decision on the drug candidate. This early ‘proof of monitor and control the anhydrate/hydrate form during the
concept’ is an alternative view for rapid, slimmed down devel- wet mixing, fluid bed drying and aqueous film coating pro-
opment both in terms of cost and time. cesses. This factor has led to the deselection of a particular
It has been shown that inadequate preformulation data is salt form in further development process many times [14,15].
one of the reasons for product recalls. The information During the drug development process, discovery of new
required on preformulation will, to a certain extent, be dic- crystal forms offers an opportunity to select an optimal form
tated by the final product, the proposed route of administra- of a drug candidate [16]. Cocrystals have also been utilized
tion and the development plan. A schematic overview of for modifying the physicochemical parameters of drugs.
preformulation characteristics is depicted in Figure 1. Tsutsumi et al. [17] studied miconazole salts and cocrystals
An extensive number of research papers have been pub- for improving physicochemical properties. They reported
lished on different techniques and protocols for estimation hemisuccinate as a novel cocrystal form of miconazole with
of preformulation parameters [8], as well as there are several an improved dissolution rate and superior stability, making
reviews [9-11] on the theoretical aspects of preformulation. it an alternative for nitrate salt. Pharmaceutical cocrystal strat-
Szunyogh et al. [10] reviewed (written in Hungarian language) egy compliments the salt formation to enhance bioavailability
the importance of decreased particle size in preformulation. of drug product and stability [18].
Hageman [9] has discussed the assessment of key physico- The information generated from preliminary crystallization
chemical properties and how they are implicated in both dis- studies is often helpful to the process chemistry group, which
covery enablement and in final product developability of investigates possible manufacturing routes for the molecule of
selected candidate. Ashizawa [11] reviewed (in Japanese lan- interest. The manufacturing route may be the same as used by
guage) the importance of physicochemical profiling and pre- the discovery chemistry group, but it can also significantly dif-
formulation studies at the drug discovery stage. However, fer. Both the process chemistry and preformulation groups
there is no review available where the significance of individ- extensively collaborate for the next 12 -- 18 months in order
ual preformulation parameters in product development is to ensure a viable synthetic route for the chosen salt form of
elaborated using case studies of drug candidates. Furthermore, the drug candidate. A significant portion of this batch is des-
a critical analysis of preformulation-related product recalls is tined for the preparation of 3 -- 4 g of each salt that were
missing in earlier reviews. The present review provides a crit- thought to be viable from smaller-scale studies. A similar-
ical account on how understanding of chemical and pharma- sized portion of free base/acid is also taken for comparison
ceutical properties of medicinal chemistry leads plays a vital purposes. The combination of individual studies undertaken
role in product development. This has been elaborated using on each of these 3 -- 4 g portions varies depending on the
case studies of drug candidates wherein preformulation data type(s) of dosage form ultimately required for marketing.
Analytical Physical
A) Molecular structure B) Chemical analysis
Physical analysis
determination I) Quantification II) Purity
a) Melting point f) Microscopy
a) Elemental a) TLC a) Synthetic impurities
b) Hygroscopicity i) Particle shape
b) NMR b) HPLC b) Residual solvent
Reverse phase c) Differential scanning calorimetry ii) Particle size
c) Mass spectrometry c) Residual water g) Powder
Chiral d) Thermogravimetry
d) IR d) Heavy metals i) Compaction
e) X-ray crystal determination
e) UV/Vis e) Degradants 1 2 ii) Flow
microbiology
Candidate drug
Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Universita Studi di Torino on 04/03/13
Pharmaceutical Physicochemical
A) Chemical stability B) Physicochemical properties
A) Biopharmaceutical properties B) Chemical compatibility 3
a) Oxidation I) Log P
a) Monolayer adsorption I) Processing
b) Light II) pKa
b) ADME II) Excipients
c) pH III) Solubility
Degradants
d) Temperature a) Solvent
C) Regulatory stability e) Solvent b) pH
c) Dissolution
Figure 1. Map of preformulation studies revolving around the candidate drug. Studies would commence in the analytical
segment and swing around to the pharmaceutical segment as the compounds’ development progressed. As early studies
For personal use only.
affect later studies, the dotted pointer indicates one linkage, the determination of the UV/VIS spectrum is useful for HPLC
method development, which is influenced by synthetic impurities and degradants, which then allows degradation studies to
be conducted [8].
Occasionally, it may be necessary to undertake a pharmacoki- penicillin G (2) was much less hygroscopic than sodium salt;
netic evaluation of each salt in comparison with the free acid/ however, penicillin G potassium tends to have an unpleasant
base. At this stage in the development process, the aim is to metallic taste [20]. Serajuddin et al. [22] observed that hydro-
quickly manufacture 50 -- 200 g of promising candidate(s) chloride salt of the poorly water-soluble drug REV-5901
for initial clinical evaluation. The alternative approach is to (3, an orally effective peptidoleukotriene antagonist) is unsta-
proceed with the free base or acid form, if the drug candidate ble due to conversion of anhydrous and monohydrate forms
displays efficacy in animal studies. In such cases, the extensive to a hydrate form at > 40% relative humidity. On loss of
process chemistry efforts can be skipped and the medicinal water at 40 -- 60 C, the hydrate form became unstable, which
chemistry synthetic route could be employed to quickly pre- was also confirmed by accelerated stability studies. However,
pare free base/acid form. Formulation strategies could be the basic form of REV-5901 was stable and pharmaceutically
employed in order to achieve adequate exposure of the drug. acceptable crystalline solid. Engel et al. [23] performed a salt
Dosage forms most commonly used for drug substances selection study on LY333531 (4), a competitive reversible
encountered during preliminary clinical investigations are tab- inhibitor of protein kinase Cb, which was being evaluated
lets/capsules, inhalation dosage forms and injections [19]. Of for treatment of diabetic complications (e.g., retinopathy
the many salts synthesized, the preferred form is selected by and erectile dysfunction). LY333531 as a free base has poor
a pharmaceutical chemist primarily on a practical basis (raw aqueous solubility and thus its salt form was desired to
materials employed, ease of crystallization process and per- enhance solubility and bioavailability. Seven salts (hydrochlo-
centage yield). Other basic considerations include stability, ride, mesylate, tartrate, sulfate, succinate, acetate and phos-
hygroscopicity and flowability of the resulting bulk drug. phate) were initially crystallized and evaluated for various
The following representative examples illustrate how and physical properties such as particle size and morphology,
why selection of proper salt forms is necessary during prefor- hygroscopicity, crystallinity and aqueous solubility in order
mulation and before going forward to product development. to find out feasibility for further development. Of the seven
The process for producing a stable chlortetracycline (1) sus- salts selected, five salts (sulfate, succinate, tartrate, acetate
pension was developed at Lederle Laboratories between and phosphate) were eliminated due to poor crystallinity,
1951 and 1954 [20]. Berge et al. [21] observed that hydrochlo- low solubility and difficulty in improving chemical purity
ride salt was highly unstable in aqueous solution, but calcium during preparation. The two remaining mesylate and hydro-
salt was very stable. They also reported that potassium salt of chloride salts were comprehensively analyzed for additional
O
H O
OH O O OH OH S H N
OH N N
OH
H2N N
N O N
O O O
O
H H OH
N HO Cl NH
2 Penicillin G 3 REV-5901
O
1 Chlortetracycline 4 LY333531
Cl N HO O S
OH H O
NH O
O O-
7 L-649923
Cl OH S
O
O O
5 Diclofenac 6 O OH
O N
Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Universita Studi di Torino on 04/03/13
OH H H
O NH2 O O
H N
N H
N N N OH N
O OH
OH HO OH H
O N N S O
N HO O N 8 Nelfinavir
10 Thiamine
9 Theophylline HO
O
O O O O OH OH
N Cl OH 11 Erythromycin OH
N H2N
S H HO
Cl
O HO O HO
O H H OH
O O N OH
HN N
NH HN +
N N 16 Oxytetracycline
N O O-
N
13 Chloramphenicol O
For personal use only.
N S S O
15 Phenylbutazone
12 Ritonavir OH
HO
H
14 Rotigotine O O
Cl N O
O
O N
S NH HN N
HN S S N
O H2N N O
O O O
N O N O
H
H O
17 Tolbutamide 18 Hydrochlorothiazide
N
N O 19 Irbesartan
O O
N N O
OH O
O S N O
NH OH
NH2 O H
I I 20 Rapamune
F OAc
21 RPR 200765 HO O
O I
N HO O
22 NBI 75043 I 23 Levothyroxine O
H3CO OH
F
N O HH
H3CO OCH3 OCH3 O
Cl OH F 24 Fluocinonide
25 Combretastatin A4 OH
HO O NH NH
O O HN N NH2
27 Warfarin
OH O
26 Flavopiridol 28 Metformin
parameters such as polymorphism, stability, purification, fil- propensity to undergo intramolecular esterification to form
terability and relative bioavailability in dogs. Results obtained g-lactone. In order to avoid formation of g-lactone, formula-
from these efforts indicated that mesylate salt can be devel- tion efforts were undertaken wherein calcium salt of drug and
oped as the optimal salt form of LY333531. tablet dosage form were chosen for formulation development.
Apart from salt form selection, the stability of the selected A direct compression method was employed in tablet
salt is imperative. Chemical and physical aspects associated manufacturing. A wet granulation process was avoided by
with preparation of pharmaceutical salt are formation of using excipients with low water content and adding sodium
hydrates, polymorphism and amorphization. These aspects carbonate as an alkalizing agent. This case demonstrated the
are also important from a technological point of view, as importance of considering microenvironment pH of the solid
they affect solubility, dissolution rate and bioavailability of to stabilize the drug product. Understanding degradation
drugs. Therefore, each pharmaceutical salt must undergo a mechanisms should be the basis for selecting the right salt
careful preformulation study in order to define experimental and developing a chemically stable solid dosage form [28,29].
Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Universita Studi di Torino on 04/03/13
conditions of its stability. Fini et al. [24] prepared salts of diclo- The possible impurities in new chemical entities (NCEs)
fenac (5) with various salt-forming agents in order to find the are also a major concern during the drug development pro-
optimally stable and soluble salt form. Diclofenac salts with cess. For profiling of genotoxic impurities, a rapid and conve-
eight different cyclic aliphatic amines, such as pyrrolidine, nient method for chemical analysis should be developed at an
piperidine, morpholine, piperazine and their N-hydroxyethyl earlier stage [30]. The recent example of the anti-HIV drug nel-
analogs, were prepared and characterized. However, these finavir mesylate (Viracept), which was withdrawn from the
salts were found to possess poor aqueous solubility as com- market has shown the importance of impurity profiling [31].
pared with diclofenac sodium. Hence, each pharmaceutical The oral formulation of nelfinavir mesylate (8) was with-
salt must undergo a careful preformulation study in order to drawn from the European market in mid-2007 due to elevated
define its solubility and stability. Ionizable and non-ionizable levels of ethyl methanesulfonate which is a potential cancer-
prodrugs can also be prepared to improve bioavailability of causing contaminant. The ethyl methanesulfonate was gener-
drug candidates. However, use of free base form of the ated as a by-product of the starting material, methane sulfonic
For personal use only.
molecule with alternative formulation strategy (nanodelivery acid [32]. This issue resulted in a recall from European regula-
systems, such as nanoparticles, liposomes, nanoemulsions/ tors to assess risk mitigation strategies for all marketed prod-
microemulsions, micelles and longer circulating half-life of ucts employing sulfonic acid counter-ions to ensure that
the drugs by PEGylation) is equally straight forward. Typi- sulfonate esters that could be potentially formed are controlled
cally, the salt formation is considered as the most practical to threshold of toxicological concern-based limits [31,33].
approach to enhance bioavailability.
The maleate salt of a basic drug dibenzo-(b,f)-oxepen- 3. Polymorphic phase transitions
10-yl-methyl-methyl-prop-2-ynyl-amine (6) was found to be
more stable than free base. This selected salt was developed 3.1 Phase transitions during product development
for oral administration in the treatment of neurodegenerative Transformations between solid phases in dosage forms often
disorders, such as Parkinson’s disease and amyotrophic lateral affects the drug release process and, therefore, it is important
sclerosis. Hard gelatin capsules of various potencies (0.25, to understand the mechanisms and kinetics of phase transfor-
2.5 and 10 mg) were selected for Phase I clinical studies. After mations and factors that may influence them [34]. The risk of
initial clinical testing using capsules in Phases I and IIA, scien- change to the physical form of the drug substance can be min-
tists decided to switch the dosage form from capsule to tablet imized by selecting a stable physical form of active pharma-
with the same potencies for the Phases IIB and III clinical ceutical ingredient (API); however, it may also adversely
studies, for commercialization purpose. Tablets were devel- affect the bioavailability of the API. Thus, based on the collec-
oped with a minimal change in composition from the capsule tive information on the bioavailability of stable, metastable
formulation to maintain continuity between developmental and least-stable forms of API, an appropriate form should
activities of two dosage forms and to ensure that their stability be selected. After selection of a suitable form of the drug,
would be similar. Tablet formulations of the maleate salt of the process of formulation and conditions also decides the
this drug showed major loss in potency and lack of mass bal- solid state of the drug in the formulation. This phenomenon
ance upon storage under accelerated stability testing. No such is referred to as processing-induced phase transitions. In the
stability problem was observed in capsules that were similar in finished tablet dosage forms, in situ transformation also
composition. Interestingly, the tablet was found to be stable affects tablet properties such as porosity, interparticulate
when it was encapsulated in a capsule shell. It was identified interactions and hardness. In situ phase transitions of
that the reason behind the instability of the drug in tablets was API in formulation has been exemplified with theophylline
conversion of salt to its free base form in the microenvironment (9) [35], thiamine hydrochloride (10) [36] and erythromycin
of tablet formulation [25-27]. (11) [37], etc. Wet massing is one of the important steps in tab-
The free base of an orally active leukotriene D4 antagonist leting, wherein Tantry et al. [38] observed complete phase
L-649923 (7) was found to be highly unstable because of its transition of stable anhydrous theophylline to theophylline
monohydrate at elevated temperatures, which resulted in a crystal shape, optical and elemental properties (e.g., vapor
decrease in its dissolution rate. There was complete conver- pressure etc.) [42]. Moreover relative bioavailability of solid
sion of stable anhydrous theophylline (A) to theophylline compounds may vary markedly from one form to another.
monohydrate (M) upon addition of water. During the drying The crystal structure affects stability and developability of
process, dehydration of the M form resulted in formation of the crystallized product. The ritonavir (12, Novir) [43] story
metastable anhydrous theophylline (A*), which was trans- illustrates the importance of transitions among crystal forms
formed to A. An increase in drying temperature accelerated (conformational polymorphism). In 1998, Abbott experi-
the A* to A transition; however, addition of PVP (a crystalli- enced a catastrophic example of physical instability of the
zation inhibitor) inhibited this transition. Interestingly, a drug ritonavir [44,45]. Until 1998, Abbott had successfully man-
phase transition was noticed with the variation in method of ufactured hundreds of batches of the life-saving anti-HIV drug
preparation of granules. The fluid-bed process produced gran- ritonavir. These batches were formulated by dissolving ritona-
ules that consisted almost completely of form A (stable form vir in polyethylene glycol/ethanol/polyoxyethylene/other com-
Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Universita Studi di Torino on 04/03/13
of theophylline), whereas the high shear method yielded mix- ponents in a soft-gelatin capsule. In the spring of that year,
ture of A and A* forms. This in situ transition led to decreased batches of the soft gelatin capsule started failing dissolution
dissolution rates of these tablets. Therefore, this phase transi- specifications. Abbott quickly established that these failures
tion between stable and metastable forms of API can have a were caused by crystallization of a new, previously unknown,
pronounced impact on product performance. less soluble polymorph of ritonavir. This new polymorph
Chakravarty et al. [36] monitored phase transformation in (form 2) had about fourfold less solubility than the old form
thiamine hydrochloride tablets on storage, which were formu- and was supersaturated in formulation. Ultimately, Abbott
lated by direct compression and wet granulation methods. Thi- had to withdraw the soft-gel product from the market to
amine hydrochloride was converted from non-stoichiometric resolve the formulation issue. Abbott scientists then investi-
hydrate (NSH) to hemihydrate (HH) in stored tablets. There gated the reason for the sudden appearance of form 2. The
were significant differences in the physicochemical properties prima facie reason for appearance of form 2 was formation of
of tablets such as tablet microstructure, compact physical prop- a poorly purging cis-impurity that acted as the template for
For personal use only.
erties and product behavior. A marked increase in disintegra- the formation of cis-ritonavir that was less soluble. Investiga-
tion time, tablet volume and hardness upon wet granulation tion at a ritonavir-manufacturing site in Italy identified a
of NSH with microcrystalline cellulose (MCC) was also possible reason for the appearance of form 2 as a result of acci-
observed. However, when tablets of NSH-MCC were formu- dental seeding with this form [46]. Such transformations,
lated by dry processing via direct compression, no change was because they affect the solubility of the drug, can complicate
observed in properties except the in situ solid form converted first-in-human trials and toxicological studies [45,47,48].
to needle-like HH crystals in all stored tablets. Longer storage Another example of solid-state instability is chloramphenicol
also led to crystal growth with reduced changes in properties. palmitate (13), which when administered in suspension form
Abbott Laboratories [37] reported dissolution failure of showed unsatisfactory clinical effect due to presence of biolog-
erythromycin tablet formulation due to formation of in situ ically less active polymorphic form A [42]. It was discovered
isomorphic dehydrate. Specific lots of 12-month stability that this compound exists in two different crystalline forms [49]:
samples of erythromycin dihydrate tablets (labeled claim the form A (b polymorphs -- biologically less active) [50] and
250 mg) failed in dissolution specifications. Lot 15, which metastable form B (a polymorph -- active modification).
had a very good initial dissolution (> 99% at 60 min) failed Upon oral ingestion of the suspension formulation of this
uniformly at the 12-month time point (71% released at drug, blood levels of form A were found to be seven times
60 min). The tableting process for erythromycin involved higher than form B [51]. The British and United States Pharma-
milling and drying, which was responsible for altering crystal- copoeias specify a limit test which places an upper permitted
linity and water content. During formulation development, limit of 10% of less active b polymorph in a chloramphenicol
erythromycin dihydrate gets dehydrated, which gradually palmitate mixture (chloramphenicol palmitate oral suspension
binds with hydroxyl-rich excipients such as Mg(OH)2, and USP) [52].
thus results in delayed dissolution process. In April 2008, Schwarz Pharma recalled transdermal
patches of the dopamine agonist rotigotine (14) (Neupro
3.2 Effect of polymorphism on bioavailability patch) in the United States and some in Europe because of
To determine stability/instability of a drug, knowledge of problems with the delivery mechanism and a quality defect.
solid-state reactions and polymorphism [39] is important. Formation of crystals of rotigotine in Neupro (a matrix design
The selected solid form of a drug for development must rotigotine transdermal system) led to the product recall and
remain stable in formulation throughout the shelf life of the subsequent discontinuation. The crystallization occurred
API [40]. For formulation development, generally crystalline because of the appearance of a new unknown polymorph of
form of drug with well defined and reproducible physical rotigotine within the patch. This new polymorph was found
properties is preferred [41]. The polymorphic form of a drug to be thermodynamically more stable and less soluble than
shows variation in solubility, melting point, density, hardness, that of the original form; therefore, it produced crystals in
patches which were visible to the naked eye as ‘snowflakes’. compression of the tablet and the flow properties of the solid
These ‘snowflake’ crystals consisted of pure rotigotine, the dif- form of the drug. For example, plate-like crystals of tolbuta-
ference being that rotigotine molecules in this new polymorph mide (17) created powder-bridging in the hopper of the tablet
had a slightly different packing structure with each other com- machine and also led to capping problems during tableting [62].
pared with the original rotigotine form. As only soluble mol- Bristol-Myers Squibb recalled antihypertensive combination
ecules of rotigotine can cross the skin, crystals must dissolve in of hydrochlorothiazide (18) and irbesartan (19) (Avapro tab-
order to release drug molecules that can be absorbed. If this lets) in January 2011, due to problems associated with dissolu-
does not occur, the amount of drug available to the patient tion of irbesartan. This reduced solubility of irbesartan in
could be reduced. Therefore, the net effect of the ‘snowflake’ certain batches was the result of formation of a secondary crys-
phenomenon is the possibility of reduced drug delivery and tal form of irbesartan. The formation of the less soluble crystal
therapeutic efficacy [53-55]. form was due to tablet manufacturing changes. Detailed inves-
Although polymorphic behavior alters the solubility of tigations revealed that an increase in granulation time resulted
Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Universita Studi di Torino on 04/03/13
drugs, it does not necessarily alter the bioavailability as evi- in formation of these secondary crystals [63].
denced by phenylbutazone (15). In 1949, phenylbutazone
was used as a potent antirheumatic drug. As it is highly hydro- 5. Chirality
phobic in nature (log P = ~ 4.15), it has very poor solubility in
acidic pH. It was observed that phenylbutazone has three Determination of chirality is a part of typical development
polymorphic forms namely form I, x and y. The maximum track activity for preformulation monitoring. Generally, one
drug concentration of form y was significantly higher over of the enantiomers does not have desired pharmacological
the form x, because form y exhibited faster dissolution rate properties and thus unwanted enantiomer should be elimi-
(50% more) over the other forms. However, it was also nated from the drug formulation. Once the separation tech-
reported that there was no significant difference in bioavail- nique is available, the inactive form should be excluded
ability parameters of form I and x as the rate of absorption considering economical point of view. Therefore, for develop-
of these crystals was identical [56-58]. ment of NCE, the resolution method of an optically active
For personal use only.
The two forms of oxytetracycline, a dihydrate form and compound should be available at earlier stages of the discovery
HCl salt form have varying stability and water solubility. process. As a regulatory requirement for IND submission, the
The former was more stable compared to HCl salt form and enantiopure form of the drug is essential. Thus, the selection
the aqueous solubility was opposite. Therefore, the relatively of right enantiomer for the market product must be decided
insoluble hydrated base in the official preparation (British before patent application and IND submission. Racemic
Pharmacopoeia, 1973) may not be entirely satisfactory due mixture can only be considered if the unwanted enantiomer
to its poor solubility. Thus, HCl salt was used for the prepa- racemizes rapidly (metabolically) to the desired enantiomer.
ration of formulations. However, Brice and Hammer in Heavy investment on wrong enantiomer can be avoided by
1969 [59] reported that 16 lots of oxytetracycline hydrochlo- selecting a therapeutically active enantiomer [64]. For example,
ride (16) capsules (250 mg) from 13 suppliers showed drug sirolimus (20) (Rapamune) marketed by Pfizer (formerly by
serum levels lower than that of the innovator product which Wyeth) is an immunosuppressive agent that was approved by
was thought to be associated with its instability. Further, in the Food and Drug Administration (FDA) in 1999. It is avail-
1974 Barber et al. [60] observed the presence of different poly- able as a clear, viscous oral solution containing 1 mg/ml siro-
morph (form A) in the formulation, which had a slow dissolu- limus and coated tablets of 1 mg sirolimus as an active
tion rate compared with other polymorphs in 0.1 M HCl. For ingredient. Inactive ingredients in the Rapamune oral solu-
example, tablets prepared using form A exhibited ~ 55% disso- tion are Phosal 50 PG and polysorbate 80 (nonaqueous
lution at 30 min, whereas the tablets prepared with form B vehicles). Sirolimus is chiral (15 stereogenic centers) and is
exhibited complete (~ 95%) dissolution at 30 min [61]. produced as a single defined stereoisomer in solid state using
asymmetric synthesis. However, in aqueous solutions this was
4. Crystal habit and druggability interconverted into three isomers (A, B and C). Therefore,
selection and use of nonaqueous vehicles during product devel-
Crystal engineering studies are important in the pharmaceuti- opment eliminated major concerns with regard to solid-
cal industry to develop stable and robust solid dosage forms. state properties of the drug substance, such as the potential
Solid-state properties have a great impact on physicochemical for polymorphic forms, particle size, surface area, intrinsic dis-
and biopharmaceutical properties of drugs. The solid state is solution rate and oral bioavailability issues of sirolimus [65-67].
important as it affects filtration, flow, tableting and dissolu-
tion. Although there may not be significant differences in bio- 6.Bulk properties (particle size and size
availability of drugs with different crystal habits, it is of distribution, flow, dissolution, etc.)
importance from a technological point of view. The injection
of a suspension-containing drug in crystal form is influenced Particle shape and size affect both primary and bulk powder
by its habit. Crystal habit also influences the ease of properties and play a decisive role in controlling dissolution [68].
Knowledge of particle size and size distribution, flow proper- chemistry team for modification of labile groups to improve
ties and dissolution are key aspects that should be studied in stability; ii) help development scientists to determine develop-
the field of dissolution science and during the formulation ability of the compound; iii) provide guidelines on compound
development process [69]. The melting point of pharmaceutical handling and storage; and iv) provide information to guide
salts is often intrinsically related to their physicochemical prop- stabilization strategies [3,48,74].
erties. The APIs with low melting points often exhibit plastic An orally administered levothyroxine sodium (23) product
deformation during the formulation development process, did not remain potent and stable through their expiration
which can cause both caking and aggregation, and has an dates. Levothyroxine sodium was first introduced into the
impact on both flow and compressibility performance. These market before 1962, without an approved new drug applica-
in turn affect many critical quality attributes of the drug tion (NDA), apparently in belief that it was not a new drug.
product (with low dose) such as disintegration and in vitro After that almost every manufacturer had regular recalls due
dissolution rates, friability and content uniformity [70]. to reason of potency or stability issues. It has been reported
Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Universita Studi di Torino on 04/03/13
Bastin et al. [19] demonstrated the importance of flow prop- that levothyroxine sodium was unstable in the presence of
erties by studying physicochemical properties of various salts light, temperature, air and humidity [75,76]. As these products
of the anti-arthritic drug RPR 200765 (21). Among four were marketed without NDAs, manufacturers need not have
salt forms investigated (mesylate, camphorsulfonate, hydro- FDA approval each time after reformulating levothyroxine
chloride and hydrobromide), mesylate salt demonstrated sodium products. Manufacturers performed formulation
good handling properties such as good flow (required during changes such as changed excipients, physical appearance of
formulation stage) and a non-hygroscopic nature, allowing coloring agents and other product aspects, which significantly
straightforward capsule and tablet development. These flow changed the potency of the drug (either decreasing or increas-
properties were superior to the alternative salts studied ing by as much as 30%). In a few cases, these formulation
(hydrochloride, hydrobromide and camphorsulfonate) [71]. changes resulted in toxicity to people who were on the same
dosage for years. With the occurrence of potency issues, the
7. Hygroscopicity US FDA classified all orally administered drug products of
For personal use only.
test systems. As most of the in vitro test conditions also product’s ability to effectively administer the drug dose.
require a pH of 7.4, there is a real chance that the concentra- Most excipients have no direct pharmacological action but
tions apparently being tested are in fact not being attained. It they impart useful properties to the formulation. Apart from
is difficult in HTS set up to ensure that the actual test concen- this, they can also give rise to inadvertent and/or unintended
trations have been achieved. Therefore, many times such tests effects such as increased drug degradation. Physical and chem-
are typically run at relatively high concentrations to ensure ical interactions between drugs and excipients may affect
adequate safety margins (e.g., hERG channel liability) [82]. chemical nature, stability and bioavailability of drug products,
This characteristic also affects future developability and for- and subsequently their therapeutic efficacy and safety [88].
mulation efforts for compounds [83]. Incorporation of additive(s) to an intravenous fluid may
Beijnen et al. [84] reported the formulation of investiga- alter inherent characteristics of the drug substance present,
tional cytotoxic drugs. Combretastatin A4 (NSC-81373, 25) resulting in parenteral incompatibility. Physical compatibility
is a natural product, isolated from dry stem wood of the South of various components in parenteral nutrition (PN) solutions
Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Universita Studi di Torino on 04/03/13
African tree Combretum caffrum, with excellent in vitro anti- has been a concern, particularly solubility of minerals such as
cancer activity, but no significant in vivo activity. Formulation calcium and phosphate [89]. A safety alert was issued by the
of combretastatin A4 was problematical due to limited aque- FDA in 1994 regarding hazards of precipitation associated
ous solubility and chemical instability of the drug in solution, with PN. Admixtures were thought to contain precipitates
which was aggravated by light. The most promising formula- of calcium phosphate and patient autopsies revealed diffuse
tion was one using the PET solvent system. PET is a mixture microvascular pulmonary emboli containing calcium phos-
of polyethylene glycol 400 (60%), polysorbate 80 (10%) and phate [90,91]. During January 1994, two patients at a federal
ethanol (to 100%). In a preliminary murine toxicological hospital died suddenly while receiving a ‘three-in-one’ (i.e.,
study, severe irritation at the injection site was noticed. amino acid, carbohydrate and lipid) peripheral PN admixture.
Attempts were also made to use other formulation approaches Clinical diagnosis in both patients was pulmonary embolism.
such as using emulsions; however, the physicochemical prop- The autopsies revealed amorphous deposits of calcium phos-
erties of combretastatin A4 did not allow these attempts to phate in pulmonary microvasculature of both patients [92].
For personal use only.
succeed. Subsequently prodrug approach showed promise The size of the particles was not evaluated, but the reason
wherein the phosphate ester proved to have adequate solubil- behind the deaths was considered to be due to a faulty mixing
ity and stability in aqueous solution; however, this candidate sequence, deficient inline filtration and a short time from
was found to be inactive in vivo and current research is compounding to administration [93,94].
directed toward identifying other suitable prodrugs. An example of therapeutic incompatibility is Coumadin
Flavopiridol [5,7-dihydroxy-8-(4-N-methyl-2-hydroxypyr- tablets. Bristol-Myers Squibb recalled Coumadin (warfarin
idyl)-6¢-chloroflavone hydrochloride, 26] is a flavonoid with sodium, 27) crystalline 5 mg tablets (lot number 9H49374A)
weak electrolyte properties and poor aqueous solubility because of efficacy issues. In these formulations, isopropanol
(0.02 mg/mL). Flavopiridol is currently under consideration was used to keep the active ingredient in a crystalline state.
as a parenteral treatment for breast tumors [85]. A number of However, poor quality isopropanol had a risk of Coumadin
methods have been tried to improve solubility of flavopiridol being less potent or overly potent and certain lots were recalled
such as cosolvency, complexation and pH control. Because of because of isopropanol not meeting quality specifications.
its low intrinsic solubility, precipitation of the solubilized Recalls in these batches were decided because if a drug becomes
drug, when diluted with blood upon injection, was a problem. less potent, there is an increased risk of blood clots, heart attack
Li et al. [86] studied precipitation of the drug in parenteral for- or stroke, and if it becomes too potent there is more risk of
mulation containing up to 10 mg/mL of flavopiridol using a bleeding [95].
static serial dilution technique. There was no precipitation Metformin (28) (Starlix), a product of Novartis, which is
in formulations containing 2 and 5 mg/mL of flavopiridol intended for treating type II diabetes, is an example of charge
in 30% 2-hydroxypropyl-b-cyclodextrin (HP-b-CD) -0.1 M interaction reported by Hollenbeck et al. [96]. Novartis
citric acid at pH 5.8 and 10 mg/mL of flavopiridol in 30% observed low percentage recovery during the analytical
HP-b-CD--0.1 M citric acid at pH 3 [86,87]. This improve- method development and validation of the combination
ment in solubility of flavopiridol was thought to be due to bilayer product Starlix. The purpose of bilayer was to separate
better solubility of the HP-b-CD complex of flavopiridol at the drug (metformin) from croscarmellose sodium. When
the abovementioned pH. these two are present in solid state, the charge interaction is
not expected due to low moisture content in the tablet
10. Physical incompatibilities (< 2%). However, in solution form, the positively charged
metformin and negatively charged croscarmellose sodium
Assessment of possible incompatibilities between drug and underwent a charge interaction, which led to a 4 -- 8% loss
excipients is a key element of preformulation. Formulation in metformin recovery in the tablets. In solution form, this
of a drug substance involves being blended with different exci- recovery was very low (between 55 -- 73%) confirming the
pients to improve its manufacturability and to maximize the interaction. This issue was resolved by incorporating arginine
into the formulations, which is a competitor for binding sites commercialization involves several steps that traditionally
on croscarmellose sodium. Arginine has stronger interaction occur in a series [118]. The average cost of taking a candidate
with croscarmellose sodium than metformin, thus, enabling from the discovery stage to commercialization is estimated
a complete recovery of metformin in tablet formulation [97]. to exceed US$800 million, with an average development
For a detailed account on interactions and incompatibilities time span of ~ 15 years, and a success rate of only 1 in
of APIs with pharmaceutical excipients, a specific review [88] 5,000 discovery candidates reaching the market [119]. HTS
on this topic should be referred to. and combinatorial chemistry technologies have been devel-
oped in the past two decades to speed up initial drug discovery
11. Biopharmaceutical aspects -- absorption, stages such as synthesis of a large number of diversely oriented
distribution, metabolism and excretion compounds and the ability to screen them quickly in a shorter
time. In contrast, these technologies have produced large
A total of 90% of compounds reaching an IND filing fail to number of ‘hits’ with poor physicochemical and ADMET
Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Universita Studi di Torino on 04/03/13
be a NDA [98]. The key factor pursued in many lead discovery properties which are responsible for high attrition rate at fur-
and optimization programs is high in vitro potency/activity ther stages of drug discovery. Several complementary in silico
(as low as in the nanomolar range). At preclinical stage, an and in vitro strategies have also emerged to screen these com-
optimization of physicochemical and biopharmaceutical pounds and assess their potential to become lead candidates.
properties such as solubility, selectivity, cellular activity and Some of the advantages of HTS may be combined with
ADMET properties may reduce the failure rate in clinical analyses of structure--activity relationships to direct rapid,
trials [99-106]. Compounds that are identified as poorly soluble sometimes automated, iterative chemistry. Prediction of
and/or which show poor bioavailability as well as cross- potency at target, potency at likely toxicity sites, potency in
species metabolism necessitates additional formulation efforts cellular assays and prediction of ADMET at early stages of
at the developmental stage [106-111]. The most cited example is drug discovery research is now gaining importance [120,121].
lopinavir (29), which is a potent antiretroviral drug. However, Compounds emerging as ‘hits’ from these screening processes
it has high plasma protein binding and poor bioavailability. are characterized further and tested in vivo for safety and
For personal use only.
Formulation in combination with ritonavir (a fixed dose com- efficacy [107]. A number of drugs have been removed from
bination, Kaletra), a CYP3A inhibitor, was then developed the market due to safety/efficacy concerns and economic
to overcome bioavailability issues [112,113]. factors [122]. Elements that are essential to take a new lead
Another antiretroviral drug, saquinavir (30) belongs to the candidate through the preclinical development process are
class of protease inhibitors. Two formulations have been numerous. These include synthesizing sufficient compound
marketed; a hard-gel capsule formulation of mesylate salt for safety assessment, formulating and characterizing drug
(Invirase) was approved in 1995, wherein ritonavir in com- product, determining the drug’s bioavailability and metabolic
bination with saquinavir was administered in order to increase profile, and conducting safety studies to determine the drug’s
saquinavir bioavailability. This hard gelatin capsule formula- toxicity. Better understanding of the chemical and pharma-
tion was poorly absorbed and led to viral resistance in many ceutical properties of newly synthesized molecules, leading
patients. For this reason, in order to improve bioavailability, to better pharmacokinetic parameters, certainly reduces the
another formulation (Fortovase) was approved in 1997 -- an failure rate of preclinical and early clinical molecules [123,124].
orally administered microemulsion in the form of a soft- After pharmacological and toxicological screening, the best
gel capsule formulation of saquinavir. In May 2005, Roche compound(s) from the biopharmaceutical point of view could
announced market withdrawal of Fortovase owing to reduction be selected based on physicochemical parameters such as sol-
in demand, possibly because Invirase boosted with ritonavir ubility, dissolution rate, lipophilicity, hygroscopicity, pKa,
was more effective compared with Fortovase [114]. Bioavailabil- polymorphism, stability and particle characteristics at earlier
ity of other protease inhibitors such as atazanavir (31) [115] stages with the highest possible accuracy. These properties
(Reyataz marketed by Bristol-Myers Squibb was approved continue to be referenced throughout API scale-up process
in 2003); darunavir (32) [116] (Prezista formerly known as chemistry and good manufacturing practices [125,126]. There-
TMC114 was approved in 2006) and etravirine (33) [117] fore, at an early stage, physicochemical studies have a signifi-
(Intelence was approved in 2008, marketed by Tibotec, a sub- cant part to play in anticipating formulation problems and
sidiary of Johnson & Johnson) were found to be increased in identifying a logical path in dosage form technology.
when given in combination with lopinavir/ritonavir. Chemical Such studies may also result in reduction of development
structures of drugs 29 -- 33 are shown in Figure 3. costs [127,128]. Successful implementation of this process results
in generation of sufficient data to file an IND application [129].
12. Preformulation and IND approval
12.1 Preformulation requisites
Drug research and development is a unique multidisciplinary Drug research is a very complicated endeavor which includes
process to identify novel therapeutic agents. The process of several diverse disciplines united with a common goal of
taking NCE from concept to clinic and eventually to developing novel therapeutic agents. Due to growing
O
NH2 N
O HO HN
HN O OH
N O
N HN NH NH HN N
N H3CO NH NH
O O
NH
O OHO O O
O HN OCH3
O
29 Lopinavir 30 Saquinavir 31 Atazanavir
H2N Br
NH2
N O
O
Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Universita Studi di Torino on 04/03/13
N
S N NH
H O HN N
O
O OH
O O
H N
32 Darunavir 33 Etravirine
complexity of drug substances, development of a quality drug and thereby poor bioavailability are high crystallinity/
product and a reproducible manufacturing process becomes high melting point and hydrophobicity or high log P value.
more challenging and costly. The method should yield consis- The n-octanol/water partition coefficient is the ratio of con-
For personal use only.
tent high-quality drug products that should not be affected by centration of compound in n-octanol to that in water under
variation within the drug substance, excipients and raw mate- equilibrium. Log P is a parameter that determines lipophilic-
rials. In the early stage of product development, a fundamen- ity of a molecule and has wide application in prediction of
tal understanding of the physicochemical properties of the biological activities and ADMET [133]. In general, if log
drug substance potentially influences performance and manu- P = 0, there is equal distribution of the drug in both phases.
facturability of the drug product. The study of physicochem- Log P > 0 is indicative that the drug is lipid soluble and
ical properties of a drug substance is usually conducted during log P < 0 means the drug is water soluble. Therefore, the
preformulation research. In general, preformulation work can higher the log P value, the higher the affinity for lipid mem-
start as early as during biological screening, in which diverse branes. Values of log P that are too high (> 5) or too low
compounds are screened for desired activity. However, an (< 3) may be associated with poor transport characteris-
extensive physicochemical characterization of a drug sub- tics [134,135]. Physicochemical and pharmacokinetic properties
stance will not usually start until one or more potential candi- of a drug will decide rationality of product development or
dates are identified and taken into clinical testing during the suitable drug delivery systems.
investigational stages. The information and knowledge gained For topical and transdermal delivery, physiochemical
from preformulation studies also help in accelerating develop- factors such as solubility, crystallinity, molecular weight
ment of new therapeutic entities. For example, selection of (< 600 Da), melting point (< 200 C) and Log P (between
compounds that have physical properties favorable for oral -1 and 4) must be considered. The higher value of Log P
absorption and certain types of process operations can facili- points to a potentially higher ease of penetration of the com-
tate rapid progress of these compounds at later stages of pound into cells of living organisms [136-138]. There is not an
drug product development. Generally, preformulation studies absolute standard for solubility or dissolution for drugs given
start with an exploration of solubility, permeability, stability, orally. The acceptable level of solubility will differ from com-
hygroscopicity, particle size, polymorphism and so on. Some pound to compound based on dose and permeability. If the
of these characteristics are interrelated and their analysis may dose is low and permeability is good, then even poorly soluble
need to be considered in combination or simultaneously [130]. compounds will be well absorbed. However, high-dose drugs
Drugs penetrate across the epithelium via transcellular or that are poorly soluble are much more likely to have limited
paracellular pathways. Lipophilic drugs prefer the transcellular solubility. These compounds are better candidates for solubil-
route and hydrophilic drugs penetrate primarily through the ity enhancement and prodrug strategies. Typically, partition
paracellular pathway, which involves passive or altered diffu- coefficients in the range of 100 -- 1,000 (log P = 2 to 3) are
sion through intercellular spaces [131]. In active transport, required for efficient passive transcellular transport. Extremely
membrane proteins act as carrier molecules to transport drugs lipophilic compounds (log P > 3.5) are associated with
across cell membranes [132]. Factors that affect poor solubility decreased absorption [139]. Compounds that have a low
aqueous solubility (< 1 mg/mL) may already possess inherent 13. Conclusion
sustained-release potential as a result of their low solubil-
ity [140]. For ophthalmic drug delivery, favorable parameters In summary, the article has provided critical account on the
of drug are: log P value of 2 to 3 and molecular weight significance of preformulation studies in the drug develop-
is < 500 Da [141]. In the case of a nasal delivery system, nasal ment process. To facilitate clinical development and to reduce
absorption drops-off sharply for lipophilic drugs with a attrition rate, a thorough study of physicochemical properties
molecular weight > 1,000 Da [142]. Drugs in a nonionized of drug candidates is desired. This also serves as the foundation
state are absorbed due to a high apparent partition coefficient for developing robust formulations.
(more lipophilic). Commonly intranasal drugs are adminis-
tered as molecularly dispersed forms such as solutions. The 14. Expert opinion
allowable volume of solution for intranasal administration
is relatively low and, therefore, drugs with low aqueous Collaboration of medicinal chemists and formulation scien-
Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Universita Studi di Torino on 04/03/13
solubility and/or requiring high doses may present a problem. tists in drug discovery research is essential to identify a drug
The profile of an ideal drug candidate for nasal delivery candidate that has the best chance of clinical and eventually
is molecular weight < 500 Da, log P < 5 and aqueous commercial success. The partnership between medicinal
solubility < 50 mg/mL [143]. Drug solubility and dissolution chemists and formulation scientists in drug discovery produ-
rate are important, especially if it is administered as a solid ces NCE with structural modifications in order to improve
dosage form (e.g., a powder). Powder morphology and parti- solubility, stability, permeability and oral bioavailability.
cle size influences amount and pattern of drug deposition The role of formulation scientists has been recognized for pre-
inside the nasal cavity [144-146]. Based on physicochemical paring formulations for preclinical in vivo studies and for
drug properties, a suitable drug delivery approach can be identification of final solid-state forms of drugs. Apart from
selected and/or drug properties can be modified in terms of this, the team work between pharmaceutics and medicinal
solubility, log P value, crystallinity, hygroscopicity and so on chemistry departments at earlier stages of drug discovery
to achieve required criteria for a targeted delivery system. increases the speed of preclinical evaluation and reduces attri-
For personal use only.
Salt selection and stability Chlortetracycline (1) Calcium salt was very stable compared to hydrochloride salt [21]
Penicillin G (2) Potassium salt was less hygroscopic, but had unpleasant metallic taste [20]
REV-5901 (3) Hydrochloride salt unstable [22]
LY333531 (4) Low aqueous solubility of free base of API; mesylate salt form was optimal [23]
Diclofenac (5) Solubility of sodium salt better than other prepared salt forms [24]
Dibenzo (b,f)oxepen-10-ylmethyl-methyl-prop-2-ynyl-amine Maleate salt was more stable than the free base [26]
hydrogen maleate (6)
L-649923 (7) Free base was very unstable, but the calcium salt was more [28]
pharmaceutically promising than the sodium, ethylenediamine
and benzathine salts
Nelfinavir mesylate (8) Withdrawn from market due to elevated levels of ethyl methanesulfonate [31]
(cancer-causing contaminant)
Polymorphic phase transitions Theophylline (9) Phase transition of stable anhydrous theophylline to [38]
theophylline monohydrate due to wet granulation, which resulted
in decrease in dissolution rate
Thiamine hydrochloride (10) Conversion of stable thiamine hydrochloride to NSH [36]
due to wet granulation
Erythromycin (11) Conversion to erythromycin dihydrate due to milling and drying [37]
Ritonavir (12) Reduced solubility in the marketed formulation due [151]
to existence of new polymorph
Chloramphenicol palmitate (13) Discovery of presence of biologically less active crystal form [42]
Rotigotine (14) Presence of less stable new polymorphic crystals [54]
Oxytetracycline hydrochloride (16) Discovery of less soluble new polymorph [60]
Crystal habit and druggability Tolbutamide (17) Plate-like crystals cause tableting problems [62]
Hydrochlorothiazide (18) and irbesartan (19) Existence of less soluble crystal of irbesartan due to longer granulation time [63]
13
S. S. Bharate & R. A. Vishwakarma
was if the microenvironmental pH rises above 1, the hydro- direction and rate of shear, storage container dimension and par-
chloride/sulfate salt gets converted to free base. Therefore, ticle--wall interaction. In the case of RPR 200765 (21), mesylate
REV-5091 was preferred as a free base over the salt forms. salt was found to have better handling properties over sulfonate,
Trace impurities found during salt formation plays a signifi- hydrochloride and hydrobromide salts.
cant role in the stability of formulations and may affect Drug stability is an essential component of preformulation
potency of API. The starting material used for salt form prep- testing and preformulation scientists collaboratively work
aration may also give rise to formation of impurities as a with analytical departments to develop stability-indicating
by-product as seen in the case of nelfinavir mesylate (8). assays. During early stages, a perfect stability-indicating assay
Another parameter to be studied during the preformulation may not be available because initial drug lots may not be pure
stage is polymorphism and phase transitions. These should be and purity is improved as the molecule progresses to subse-
investigated during initial stages of development. In situ phase quent development stages. Therefore, the intention of prefor-
transitions during product development (manufacturing mulation scientists is to broadly define conditions under
Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Universita Studi di Torino on 04/03/13
processes and processing conditions) may affect/alter solubil- which the drug would be stable. In the case of levothyroxine
ity of drug and thus the bioavailability. The manufacturing sodium (23) it was not stable throughout its shelf life and after
processes such as wet granulation [as in case with theophylline marketing it was found that the reason behind less potency
(9), thiamine HCl (10)], milling and drying [as observed with was a stability issue with levothyroxine sodium. It was sensi-
erythromycin (11)] may have pronounced effect on dissolu- tive to light, temperature, air and humidity, thus, loss of
tion rate and stability of drugs. Results of these studies must potency was the reason behind product recall.
be incorporated in the CMC section of NDA. This informa- Determination of solubility during preformulation testing
tion is required to demonstrate control over manufacturing is a decisive parameter during formulation development. Drug
processes. Existence of different crystal forms should be stud- solubility is one of the physicochemical parameters that receive
ied because it may impart either harmful or helpful character- a lot of attention during preformulation testing. The BCS para-
istics to particular formulations in terms of bioavailability. digm can be used to develop strategies for enhancing drug solubil-
The most cited example is ritonavir (12) and oxytetracycline ity and/or permeability. Generally, the absorption rate constant of
For personal use only.
HCl (16) wherein new polymorphic forms have less solubility drugs varies by over only ~ 50-fold range (0.001 -- 0.5 mg/min)
and thus reduced bioavailability. Discovery of a new crystal whereas drug solubility can vary over six orders of magnitude
form of chloramphenicol palmitate (13) was biologically less (0.1 µg/mL -- 100 mg/mL) [150]. Hence, the formulator has supe-
active thus making formulation less effective. In the case of rior flexibility in altering the drug’s solubility over its permeabil-
rotigotine (14), the new polymorph discovered was less stable. ity. Optimization of drug solubility may be more fruitful if
For this reason, polymorphic study is crucial during the pre- permeability is overcome by increasing drug solubility, to provide
formulation stage and will decide commercial success of the high drug concentration at the absorption site. However, this may
final product. The crystal structure of a compound will decide be difficult if the dose is very high. Alternative formulation
its physicochemical properties such as crystal habit, melting approaches could be considered if the drug is poorly soluble. In
point, solubility, rate of desolvation, color, mechanical prop- the case of flavopiridol (26), researchers formulated flavopiridol
erties and chemical stability. Plate-like crystals of tolbutamide with HP-b-CD and citric acid to keep the drug in a solubilized
(17) were not suitable for tableting and, therefore, not manu- form so that it would not precipitate upon injection.
facturable. Thus, understanding of these properties during The role of the preformulation team at every stage of the
product development will be beneficial. drug discovery and development process is to select appropriate
In the pharmaceutical scenario, particle size and size distri- methods to guide or alert other development teams about drug
bution affects the intrinsic dissolution rate, which is one of the solubility and permeability issues. There have been consequences
decisive parameters of drugs after administration. Shape char- observed of formation of new impurities, incomplete mass bal-
acterization is vital here as different crystal faces dissolve at dif- ance, destruction of dosage form, unnecessary multiplicity of pro-
ferent rates. At the preformulation stage, one should identify totype formulations and changes in physicochemical properties
particle shape and size distribution in order to produce formula- (stability, solubility, dissolution profile, degree of crystallinity
tions with desired efficacy and with economical production tech- and hygroscopicity) due to inadequate data on the drug--excipient
niques. Good flow properties are preconditions for successful interaction. The reason behind this might be incomplete/
manufacturing of dosage forms (tablets and hard gelatin capsu- insufficient drug--excipient interaction studies at the preformula-
les). Appropriate fluidity of materials is required for transporta- tion stage, which can be one reason for inability to obtain success-
tion of powder fill/granules through the hopper of the tableting ful drug registration. The bilayer tablet of metformin (28) was
machine. Elongated particle shape and small particle size may recalled due to a very low recovery of API. This has been attrib-
cause high tablet weight variations, strength, unacceptable blend uted to the use of a negatively charged excipient (i.e., croscarmel-
uniformity and difficulty in filling containers and dies. Powder lose sodium), which had an interaction with metformin.
flow is affected by numerous parameters including purity, crystal- Throughout the process of drug discovery, a carefully
linity, electrostatic forces, mechanical properties (brittleness, planned preformulation study provides crucial data and
elasticity), density, size, shape, surface area, moisture content, information regarding drug substance and knowledge of
Bibliography
Papers of special note have been highlighted as 11. Ashizawa K. Physicochemical profiling 22. Serajuddin A, Sheen P, Mufson D, et al.
either of interest () or of considerable interest and preformulation studies at the drug Preformulation study of a poorly
() to readers. discovery stage. Nihon Yakurigaku Zasshi water-soluble drug, alpha-pentyl-3-(2-
2006;127:213-16 quinolinylmethoxy)benzenemethanol:
1. Basak AK, Raw AS, Hakim AHA, et al.
12. Thackaberry E. Non-clinical toxicological selection of the base for dosage form
Pharmaceutical impurities: regulatory
considerations for pharmaceutical salt design. J Pharm Sci 1986;75:492-6
perspective for Abbreviated New Drug
Applications. Adv Drug Deliv Rev selection. Expert Opin Drug 23. Engel GL, Farid NA, Faul MM, et al.
Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Universita Studi di Torino on 04/03/13
development. J Pharm Sci polymorphism. J Pharm Sci of heat and compromised skin.
2010;99:2948-61 1969;58:911-29 J Pharm Sci 2010;99:2357-66
.. An excellent review on polymorphism.
32. Elder D, Facchine KL, Levy JN, et al. 54. Chaudhuri KR. Crystallisation within
An approach to control strategies for 43. Kempf DJ, Marsh KC, Denissen JF, transdermal rotigotine patch: is there
sulfonate ester formation in et al. ABT-538 is a potent inhibitor of cause for concern? Expert Opin
pharmaceutical manufacturing based on human immunodeficiency virus protease Drug Deliv 2008;5:1169-71
recent scientific understanding. and has high oral bioavailability in 55. Schwarz Pharma. 2008. Prescription
Org Process Res Dev 2012;16:1707-10 humans (acquired immunodeficiency Patch Neupro Recall
33. Teasdale A, Delaney EJ, Eyley SC, et al. syndrome/antiviral/peptidomimetic).
56. Pandit JK, Gupta SK, Gode KD, et al.
A detailed study of sulfonate ester Proc Natl Acad Sci USA 1995;92:2484-8
Effect of crystal form on the oral
formation and solvolysis reaction rates 44. Bauer J, Spanton S, Henry R, et al. absorption of phenylbutazone.
and application toward establishing Ritonavir: an Extraordinary Example of Int J Pharm 1984;21:129-32
sulfonate ester control in pharmaceutical Conformational Polymorphism.
57. Kato Y, Kohketsu M. Relationship
Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Universita Studi di Torino on 04/03/13
68. Scott RR. A practical guide to equipment 81. Yang Y, Engkvist O, Llinas A, et al. parenteral nutrition admixture.
selection and operating techniques. In: Beyond size, ionization state, and Infect Control Hosp Epidemiol
Lieberman HA, Rieger MM, Banker GS, lipophilicity: influence of molecular 1997;18:814-17
editors. Pharmaceutical dosage forms: topology on absorption, distribution, 93. Doessegger L, Mahler H-C, Szczesny P,
disperse systems. Volume 2, Marcel metabolism, excretion, and toxicity for et al. The potential clinical relevance of
Dekker, New York; 1989 druglike compounds. J Med Chem visible particles in parenteral drugs.
69. Hickey AJ, Smyth HDC. A practical 2012;55:3667-77 J Pharm Sci 2012;101:2635-44
guide to equipment selection and 82. Guth BD, Rast G. Dealing with hERG 94. Bouchoud L, Fonzo-Christe C,
operating techniques. In: Hickey AJ, liabilities early: diverse approaches to an Sadeghipour F, et al. Maximizing
Smyth HDC, editors. Pharmaco- important goal in drug development. calcium and phosphate content in
complexity, outlines in pharmaceutical Br J Pharmacol 2010;159:22-4 neonatal parenteral nutrition solutions
sciences. American Association of 83. Lipinski CA. Drug-like properties and using organic calcium and phosphate
Pharmaceutical Scientists, Texas; 2011 the causes of poor solubility and poor salts. JPEN J Parenter Enteral Nutr
Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Universita Studi di Torino on 04/03/13
105. Chan OH, Stewart BH. Physicochemical 118. Brittain HG. Introduction and overview 131. Jarvinen K, Jarvinen T, Urtti A. Ocular
and drug-delivery considerations for oral to the preformulation development of absorption following topical delivery.
drug bioavailability. Drug Discov Today solid dosage forms. In: Adeyeye MC, Adv Drug Deliv Rev 1995;16:3-19
1996;1:461-73 Brittain HG, editors. Preformulation in 132. Peterson AM. Pharmacokinetic basis of
106. Lipinski CA. Experimental and solid dosage form development. Informa therapeutics and pharmacodynamic
computational approaches to estimate Healthcare USA, Inc, New Jersey, USA; priciples. In: Arcangelo VP,
solubility and permeability in drug 2008 Peterson AM, editors.
discovery and development settings. 119. Chaubal MV. Application of formulation Pharmacotherapeutics for advanced
Adv Drug Deliv Rev 2001;46:3-26 technologies in lead candidate selection practice: a practical approach. 2nd
107. Panchagnula R, Thomas NS. and optimization. Drug Discov Today edition. Lippincott Williams and
Biopharmaceutics and pharmacokinetics 2004;9:14:603-9 Wilkins, Philadelphia, USA; 2006
in drug research. Int J Pharm 120. Scannell JW, Blanckley A, Boldon H, 133. Katritzky AR, Kuanar M, Slavov S, et al.
2000;201:131-50 et al. Diagnosing the decline in Quantitative correlation of physical and
Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Universita Studi di Torino on 04/03/13
108. Kibbey CE, Poole S, Robinson B, et al. pharmaceutical R&D efficiency. Nat Rev chemical properties with chemical
An integrated process for measuring the Drug Discov 2012;11:191-200 structure: utility for prediction.
physicochemical properties of drug 121. Devadasu VR, Bhardwaj V, Chem Rev 2010;110:5714-89
candidates in a preclinical discovery Kumar MNVR. Can controversial 134. Hillery AM. The basic concepts. In:
environment. J Pharm Sci nanotechnology promise drug delivery? Hillery AHM, Lloyd AW, Swarbrick J,
2001;90:1164-75 Chem Rev 2013;113:1686-735 editors. Drug delivery and targeting: for
109. Cheng A, Merz KM Jr. Prediction of 122. Preziosi P. Science, pharmacoeconomics pharmacists and pharmaceutical scientists.
aqueous solubility of a diverse set of and ethics in drug R&D: a sustainable 1st edition. Taylor and Francis, London;
compounds using quantitative future scenario? Nat Rev Drug Discov 2001
structure-property relationships. 2004;3:521-6 135. Leeson P. Drug discovery: chemical
J Med Chem 2003;46:3572-80 123. Clark DE. In silico prediction of beauty contest. Nature 2012;481:455-6
110. Chen XQ. Prediction of aqueous blood--brain barrier permeation. 136. Potts R, Guy R. Predicting skin
For personal use only.
solubility of organic compounds using a Drug Discov Today 2003;8:927-33 permeability. Pharm Res 1992;9:663-9
quantitative structure-property 124. Clark DE. Outsourcing lead 137. Hussain A, Ahsan F. The vagina as a
relationship. J Pharm Sci optimization: constant change is here to route for systemic drug delivery.
2002;91:1838-52 stay. Drug Discov Today 2007;12:62-70 J Control Release 2005;103:301-13
111. Parrott N, Lave T. Prediction of 125. Steinmetz KL, Spack EG. The basics of 138. Denet A-R, Vanbever R, Preat V. Skin
intestinal absorption: comparative preclinical drug development for electroporation for transdermal and
assessment of GASTROPLUS and IDEA. neurodegenerative disease indications. topical delivery. Adv Drug Deliv Rev
Eur J Pharm Sci 2002;17:51-61 BMC Neurol 2009;9(Suppl 1):S2 2004;56:659-74
112. Rowland M, Peck C, Tucker G. doi:10.1186/471-2377-9-S1-S2 139. Taylor MD. Improved passive oral drug
Physiologically-based pharmacokinetics in 126. Mangin D, Puel F, Veesler S. delivery via prodrugs. Adv Drug
drug development and regulatory science. Polymorphism in processes of Deliv Rev 1996;19:131-48
Annu Rev Pharmacol Toxicol crystallization in solution: a practical 140. Collett J, Moreton C. Modified-release
2010;51:45-73 review. Organ Proc Res Dev peroral dosage forms In: Aulton M,
113. Capparelli EV, Holland D, Okamoto C, 2009;13:1241-53 editor. Pharmaceutics -- the science of
et al. Lopinavir concentrations in 127. Fontana L, Rosati L, Sala A, et al. dosage form design. 2nd edition.
cerebrospinal fluid exceed the 50% Physico-chemical parameters of nitrate Churchill Livingstone, Edinburgh, UK;
inhibitory concentration for HIV. AIDS esters. A contribution to the choice of a 2001
2005;19:949-52 candidate for preclinical development. 141. Gibson M. Ophthalmic dosage forms.
114. Withdrawal of Fortovase. Available from: Pharm Acta Helv 1996;71:341-3 In: Gibson M, editor. Pharmaceutical
http://www.rocheusa.com/products/ 128. Banker GS, Rhodes CT. A view to the preformulation and formulation --
FTVDearDoctorFINAL.pdf [Accessed on future. In: Swarbrick J, editor. a practical guide from candidate drug
9 September 2012] Modern pharmaceutics. Marcel Dekker, selection to commercial dosage form.
115. Available from: http://en.wikipedia.org/ New York; 1989 2nd edition. Informa Healthcare USA,
wiki/Atazanavir [Accessed on 129. Graffeo A. The do’s and don’ts of Inc., New York; 2009
25 September 2012] preclinical development. Biotechnology 142. Bahadur S, Pathak K. Physicochemical
116. Available from: http://en.wikipedia.org/ 1994;12:865-9 and physiological considerations for
wiki/Darunavir [Accessed on 130. Lin JH, Lu AYH. Role of efficient nose-to-brain targeting.
25 September 2012] pharmacokinetics and metabolism in Expert Opin Drug Deliv 2012;9:19-31
117. Available from: http://en.wikipedia.org/ drug discovery and development. 143. Singh RM, Kumar A, Pathak K.
wiki/Etravirine [Accessed on Pharmacol Rev 1997;49:403-49 Mucoadhesive in situ nasal gelling drug
25 September 2012] delivery systems for modulated drug
delivery. Expert Opin Drug Deliv In: Adeyeye MC, Brittain HG, editors. Pharm Sci Technol Today
2013;10:115-30 Preformulation in solid dosage form 1998;1:387-93
144. Behl CR, Pimplaskar HK, Sileno AP, development. Informa Healthcare USA, 151. Bauer J, Spanton S, Henry R, et al.
et al. Effects of physicochemical Inc, New York; 2008 Ritonavir: an extraordinary example of
properties and other factors on systemic 148. Brittain HG. Overview of physical conformational polymorphism.
nasal drug delivery. Adv Drug Deliv Rev characterization methodology. In: Pharm Res 2001;18:859-66
1998;29:89-116 Brittain HG, editor. Physical
145. Taylor P. Nasal drug delivery. characterization of pharmaceutical solids. Affiliation
In: Aulton ME, editor. Pharmaceutics -- Volume 70, Marcel Dekker Inc, USA; Sonali S Bharate1 & Ram A Vishwakarma†2
1995 †
the science of dosage form design. 2nd Author for correspondence
1
edition. Churchill Livingstone, 149. DiFeo TJ. Drug product development: Indian Institute of Integrative Medicine (CSIR),
Edinburgh, UK; 2001 a technical review of chemistry, Canal Road, Jammu-180001, India
2
146. Costantino HR, Illum L, Brandt G, manufacturing, and controls information Director,
Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Universita Studi di Torino on 04/03/13
147. Lee SL, Raw AS, Yu L. Significance of 150. Curatolo W. Physical chemical properties
drug substance physicochemical of oral drug candidates in the discovery
properties in regulatory quality by design. and exploratory development settings.
For personal use only.